"the FDA indicated that the proposed Phase 3 program is acceptable. In addition, the company announced that the FDA communicated that after their initial review of the chronic toxicology program, the programs studies appeared adequate to support the safety of IMC-1 at the proposed dose for use in treating fibromyalgia"
Keep buying...toxicology program was accepted by the FDA.... partnership next.
News 
Market Data 
Discover 
